Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01461941 | A Phase 2 Study of E6005 in Patients With Atopic Dermatitis | PHASE2 | COMPLETED | 78 | — | — | Dec 1, 2011 | Jan 1, 2013 | Jun 3, 2025 | 10 | Japan |
| NCT01179880 | A Study of E6005 in Japanese Patients With Atopic Dermatitis | PHASE1 | COMPLETED | 40 | — | — | Sep 1, 2010 | Dec 1, 2012 | Jun 4, 2025 | 1 | Japan |
| Arm | Type | Description |
|---|---|---|
| Drug: 0.2% E6005 ointment | EXPERIMENTAL | - |
| Drug: 0.0% E6005 ointment (vehicle) | PLACEBO_COMPARATOR | - |
| 1 | EXPERIMENTAL | - |
| 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| E6005 | DRUG | 0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1. |
| E6005 ointment (vehicle) | DRUG | 0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1. |
| Placebo | DRUG | Matching placebo for each step |
Inclusion Criteria * Adults of both genders aged 20 to 64 years at the time when the written informed consent is obtained. * Outpatients diagnosed with atopic dermatitis. Exclusion Criteria * Patients with a present illness of Kaposi's varicelliform eruption, scabies, molluscum contagiosum, impet...